Hotchkis & Wiley Capital Management LLC lessened its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 8.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 637,717 shares of the company's stock after selling 62,530 shares during the period. Hotchkis & Wiley Capital Management LLC owned about 0.25% of HCA Healthcare worth $259,187,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. FMR LLC increased its stake in HCA Healthcare by 322.3% in the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company's stock valued at $1,276,909,000 after buying an additional 2,397,883 shares during the period. Lee Danner & Bass Inc. acquired a new position in shares of HCA Healthcare during the second quarter valued at $131,527,000. Darsana Capital Partners LP raised its position in HCA Healthcare by 53.3% during the second quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company's stock valued at $369,472,000 after acquiring an additional 400,000 shares in the last quarter. Holocene Advisors LP increased its holdings in HCA Healthcare by 210.6% during the 3rd quarter. Holocene Advisors LP now owns 306,796 shares of the company's stock valued at $124,691,000 after purchasing an additional 208,015 shares in the last quarter. Finally, Argent Capital Management LLC grew its position in HCA Healthcare by 1,215.6% in the second quarter. Argent Capital Management LLC now owns 160,275 shares of the company's stock valued at $51,493,000 after purchasing an additional 148,092 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company's stock.
In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares of the company's stock, valued at $18,445,700. The trade was a 6.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michael S. Cuffe sold 8,358 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the transaction, the executive vice president now directly owns 29,678 shares of the company's stock, valued at $11,438,494.76. This represents a 21.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,155 shares of company stock worth $5,608,990 in the last 90 days. Insiders own 1.70% of the company's stock.
NYSE:HCA opened at $327.62 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The firm has a 50-day moving average price of $371.88 and a 200 day moving average price of $358.84. HCA Healthcare, Inc. has a 12-month low of $250.67 and a 12-month high of $417.14. The firm has a market capitalization of $82.99 billion, a PE ratio of 14.71, a price-to-earnings-growth ratio of 1.26 and a beta of 1.63.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Stockholders of record on Friday, December 13th will be given a $0.66 dividend. The ex-dividend date is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.81%. HCA Healthcare's dividend payout ratio (DPR) is currently 11.85%.
A number of analysts recently commented on the company. StockNews.com lowered HCA Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Cantor Fitzgerald restated an "overweight" rating and issued a $392.00 price target on shares of HCA Healthcare in a research report on Tuesday, October 1st. Morgan Stanley began coverage on shares of HCA Healthcare in a research note on Tuesday, September 3rd. They set an "equal weight" rating and a $427.00 price objective for the company. KeyCorp reduced their price objective on HCA Healthcare from $475.00 to $420.00 and set an "overweight" rating for the company in a research note on Monday, October 28th. Finally, TD Cowen reduced their price objective on shares of HCA Healthcare from $450.00 to $440.00 and set a "buy" rating for the company in a research report on Monday, October 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $380.29.
Read Our Latest Report on HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.